Get the Stockscreener App
2.519
3.00%
-0.071
23 Andme Holding Co stock is traded at $2.519, with a volume of 110.40K.
It is down -3.00% in the last 24 hours and down -36.56% over the past month.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
See More
Previous Close:
$2.59
Open:
$2.59
24h Volume:
110.40K
Relative Volume:
0.36
Market Cap:
$69.27M
Revenue:
$247.99M
Net Income/Loss:
$-521.97M
P/E Ratio:
-2.2694
EPS:
-1.11
Net Cash Flow:
$-194.28M
1W Performance:
-18.95%
1M Performance:
-36.56%
6M Performance:
-66.43%
1Y Performance:
-82.67%
1-Day Range:
$2.50
$2.62
1-Week Range:
$2.50
$3.08
52-Week Range:
$2.50
$16.52
23 Andme Holding Co Stock (ME) Company Profile
Name
23 Andme Holding Co
Sector
Industry
Phone
(650) 938-6300
Address
223 N. MATHILDA AVE., SUNNYVALE
Compare ME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ME
23 Andme Holding Co
|
2.5191 | 69.27M | 247.99M | -521.97M | -194.28M | -1.11 |
|
TMO
Thermo Fisher Scientific Inc
|
572.61 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
207.63 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
145.82 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
459.15 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
208.10 | 36.97B | 15.32B | 1.41B | 1.96B | 7.62 |
23 Andme Holding Co Stock (ME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-22 | Initiated | Berenberg | Buy |
| Sep-22-22 | Initiated | Cowen | Outperform |
| Nov-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Initiated | Credit Suisse | Outperform |
| Jul-12-21 | Initiated | Citigroup | Buy |
23 Andme Holding Co Stock (ME) Latest News
23andMe Launches New Genetic Report on Osteoporosis - GlobeNewswire
23andMe On The Brink? Exploring a Potential Sale Amid Financial Struggles! - Smartkarma
23andMe Sags on New Report - Baystreet.ca
23andMe Holding Co. (ME) Launches New Genetic Report on Osteoporosis - StreetInsider.com
23andMe (NASDAQ:ME) Posts Earnings Results - MarketBeat
23andMe Faces Financial Challenges Amid Revenue Growth - TipRanks
23Andme Holding Co earnings missed by $0.86, revenue topped estimates - Investing.com India
23andMe Board Explores Strategic Alternatives Amid Restructuring - GuruFocus.com
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results - GlobeNewswire
23andMe Holding Begins Exploring Strategic Alternatives -January 29, 2025 at 03:49 am EST - Marketscreener.com
23andMe Holding Co. (ME) Reports Q3 Loss of $1.02 - StreetInsider.com
ME23andMe Holding Co. Latest Stock News & Market Updates - StockTitan
23andMe says it's exploring alternatives, including a sale (ME:NASDAQ) - Seeking Alpha
23andMe Special Committee Announces Exploration of Strategic Alternatives - The Manila Times
23andMe Holding Co. (ME) to explore strategic alternatives, including possible sale - StreetInsider.com
23andMe Puts Itself Up for Sale: Major DNA Testing Company Could Change Hands - StockTitan
23andMe Holding Co. (ME) Halted, News Pending - StreetInsider.com
ME INVESTIGATION ALERT: 23andMe Holding Co. Shareholders are Alerted to Contact BFA Law regarding Ongoing Investigation into the Company (Nasdaq:ME) - ACCESS Newswire
Deal Dispatch: Lovely Day To Sell Guinness? Plus, 23andMe To Rid Lineage Of Lemonaid - Benzinga
Predictive Genetic Testing and Consumer Genomics Market Research 2024-2034: Expanding DTC Genetic Testing, Consumer Interest in Personalized Healthcare, Awareness of Early Detection and Prevention - GlobeNewswire Inc.
23andMe Has Been Reportedly Quietly Explores a Possible Sale of its Telehealth Business, Lemonaid - Marketscreener.com
23andMe launches Discover23 to help accelerate genetics research - European Pharmaceutical Manufacturer
NewView Capital Partners I LLC Has $3.16 Million Holdings in 23andMe Holding Co. (NASDAQ:ME) - MarketBeat
Jane Street Group LLC Sells 1,561,678 Shares of 23andMe Holding Co. (NASDAQ:ME) - MarketBeat
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted Technology - The Manila Times
23andMe Launches Discover23 to Help Accelerate Large-Scale - GlobeNewswire
23andMe Launches Discover23 Platform with Massive 4.7B Genetic Data Points for Medical Research - StockTitan
23andMe (NASDAQ:ME) Stock Price Down 0.3%Should You Sell? - MarketBeat
3 Promising US Penny Stocks With Over $9M Market Cap - Yahoo Finance
23andMe Stock Price Prediction: 2024, 2025, 2030 - Benzinga
23andMe Holding Co. (NASDAQ:ME) Short Interest Down 16.6% in November - MarketBeat
23Andme Holding Co earnings missed by $2.16, revenue topped estimates - Investing.com Nigeria
US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St
Wojcicki ‘Committed’ to Taking 23andMe Private as Board Quits - MSN
23andMe (NASDAQ:ME) Trading 13.1% HigherHere's Why - MarketBeat
23andMe CEO Anne Wojcicki responds to critics, shares plan for company's future: "Essential for us to restructure" - CBS News
23andMe’s stock falls after company says there’s substantial doubt it can stay in business - MSN
23andMe shares dip as Q2 loss widens despite revenue beat By Investing.com - Investing.com Nigeria
Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential? - Insider Monkey
Struggling 23andMe Is Exploring Splitting the DNA Company in Two - MSN
23andMe inks research deal with Mirador Therapeutics By Investing.com - Investing.com Canada
23andMe to slash 40% of its workforce, end therapeutics program to cut costs - MSN
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation - The Manila Times
23andMe inks research deal with Mirador Therapeutics - Investing.com India
23 Andme Holding Co Stock (ME) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.49%
3.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):